Q1 Revenue Misses, Net Loss Widens Despite EPS Beat Aided by Accounting Change
TMCI sits 71% above its 52-week low of $1.17.
Summary
Treace Medical Concepts reported a Q1 revenue decline and increased net loss, though EPS beat estimates, partly due to an accounting change.
Key Events · Earnings and Guidance · TMCI
-
Q1 2026 Financial Results
Reported revenue of $47.2 million, a 10.2% decrease from $52.6 million in Q1 2025. Net loss widened to $18.0 million ($0.28 per share) from $15.9 million ($0.25 per share) in Q1 2025.
-
EPS Beat Analyst Expectations
The reported Q1 EPS loss of $0.28 per share was better than the analyst forecast of a $0.31 per share loss, as previously reported on May 8, 2026.
-
Accounting Estimate Change Impacts Results
Effective January 1, 2026, the company extended the useful life of capitalized surgical instruments from three to five years, decreasing Q1 depreciation expense by $1.2 million and improving loss per share by $0.02. This change is expected to reduce depreciation by $4.6 million for the full year 2026.
-
Liquidity and Debt Position
Cash and cash equivalents decreased to $9.5 million from $10.7 million at year-end 2025. The company has access to a $175 million debt facility, with $60 million drawn and an undrawn $30 million revolving loan facility (borrowing base $20.6 million), providing liquidity for at least the next twelve months.
Analysis · TMCI · Industrial Applications And Services
Treace Medical Concepts reported a significant year-over-year revenue decline and a widening net loss for Q1 2026. While the company's reported EPS loss of $0.28 per share was better than analyst expectations, this was partially influenced by a change in accounting estimate for surgical instrument depreciation, which reduced depreciation expense by $1.2 million and improved EPS by $0.02. The company's liquidity position is supported by its $175 million debt facility, with $60 million drawn and additional tranches available, but the underlying operational performance shows challenges in a competitive market. Investors should monitor revenue trends and the impact of new product adoption.
At the time of this filing, TMCI was trading at $2.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $124.4M. The 52-week trading range was $1.17 to $7.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.